Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Daily Grime - OPM/PAG

ByJeremy Grime
Published 26/11/2019, 11:25
Updated 09/07/2023, 11:32

News

  • Augmentun Fintech has delayed its results pending the launch of Zopa as a bank. The company’s holding in Zopa was valued at £21.9m at March 2019, some 17% of NAV. Excluding Zopa a £10.6m NAV uplift (8.3%) is expected over the 6 months to September. The shares trade at an 8% discount to this.

  • Draper Esprit (LON:GROW) announces a 12% increase in gross portfolio value in 6 months to September.NAV was up 10% to £571m. Shares trade at a 4% discount.

    • OnePM – New Funding Facilities

    Share Price 32p

    Mkt Cap £29m

    Conflict Disclosure: No Holding

  • Funding The £7.5m medium term note has been extended to £25m. The price isn’t disclosed although I recall it being in the region of 7.5%. A further £5m has been negotiated on the block discounting facility.

  • Estimates Current year estimates to May 2020 are based on a £11.5m increase in the loan book. The company reports robust demand for funding and it may be it is growing its loan book faster.

  • Valuation PER 4.9X Yield 3.4%. Price/book 0.6X but Price/NTAV 1.2X. ROE is 12.5%.

  • Conclusion The shares have actually increased by c 28% in the last 3 months. Just possibly the market may start to believe the model is sustainable. The shares could double from here if the company continues to deliver.

    • Paragon Banking Group PLC (LON:PARA) – FY Results

    Share Price 503p

    Mkt Cap £1.29bn

    Conflict Disclosure: No Holding

  • Results Lending was up 8.5% to £2.3bn which increased the loan book by a modest 0.5% to £12.2bn. NIM improved modestly to 229bps while cost of risk increased from 6bps to 7bps and the cost income ration increased from 40.6% to 42.1%. PBT was consequently up 5% to £164.4m while the CET1 ratio was 13.7%. Dividend up 9.3% to 21.2p. The outlook refers to profitability and future earnings strength but does no anticipate significant expansion of lending volumes in the year ahead in buy to let while no new deals have been completed at Idem Capital in the last year. Commercial lending is only 12% of the loan book.
    • 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

  • Estimates PBT is politely ahead of consensus and a 4% PBT increase is anticipated in the year ahead to £171.1m

  • Valuation PER is 10.4X and yield 4.1%. ROE 12.5% and Price/book 1.2X.

    • Conclusion The company is looking ex growth at this stage of the cycle, so the only reason to own the stock is valuation. The shares are up 28% in the last 3 months on the back of the markets new found interest in value stocks. Looks like a time to take profits.

    Latest comments

    Install Our App
    Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
    Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
    Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
    It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
    Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
    © 2007-2024 - Fusion Media Limited. All Rights Reserved.